SCHEMBL23247477

SCHEMBL23247477

C=C(C)C(=O)N1CCCCC1c1ncc(-c2ccc(C)cc2)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PRCP P42785 7/20 0.58
HCRTR1 O43613 3/20 0.51
HCRTR2 O43614 3/20 0.51
CYP3A4 P08684 3/20 0.50
CYP2C9 P11712 3/20 0.50
NR1I2 O75469 1/20 0.50
ABCB11 O95342 1/20 0.50
OPRK1 P41145 1/20 0.50
KCNH2 Q12809 1/20 0.50
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23247772 0.89 PRCP (0.58) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247504 0.88 PRCP (0.57) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247560 0.87 PRCP (0.64) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247313 0.86 PRCP (0.54) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL29666088 0.86 PRCP (0.61) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247438 0.86 PRCP (0.61) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247941 0.85 PRCP (0.56) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247554 0.84 CYP3A4 (0.61) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23247921 0.84 PRCP (0.67) PRCPHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL23248000 0.83 CYP3A4 (0.58) PRCPHCRTR1HCRTR2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 US claimed
US-12528801-B2 Substituted azacyles as TRPM8 modulators GIVAUDAN SA (CH) 2026-01-20 US claimed
US-20250387310-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT FIRMENICH INCORPORATED (US) 2025-12-25 US claimed
EP-4525821-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT Firmenich Incorporated (US) 2025-03-26 EP claimed
CN-114555594-B Substituted azacycles as TRMP modulators 奇华顿股份有限公司 2025-03-18 CN claimed
US-20240358611-A1 COMPOSITIONS SYMRISE AG (DE) 2024-10-31 US claimed
EP-4387587-A1 COMPOSITIONS Symrise AG (DE) 2024-06-26 EP claimed
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2024-04-25 US claimed
CN-117813077-A Composition and method for producing the same 西姆莱斯股份公司 2024-04-02 CN claimed
WO-2024011086-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT FIRMENICH INCORPORATED (US) 2024-01-11 WO claimed
WO-2023021012-A1 COMPOSITIONS SYMRISE AG (DE) 2023-02-23 WO claimed
EP-4045491-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS Givaudan SA (CH) 2022-08-24 EP claimed
CN-114555594-A Substituted azaheterocycles as TRMP8 modulators 奇华顿股份有限公司 2022-05-27 CN claimed
WO-2021074281-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2021-04-22 WO claimed
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 US disclosed
US-12528801-B2 Substituted azacyles as TRPM8 modulators GIVAUDAN SA (CH) 2026-01-20 US disclosed
US-20250387310-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT FIRMENICH INCORPORATED (US) 2025-12-25 US disclosed
EP-4045491-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS Givaudan SA (CH) 2022-08-24 EP disclosed
CN-114555594-A Substituted azaheterocycles as TRMP8 modulators 奇华顿股份有限公司 2022-05-27 CN disclosed
WO-2021074281-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS TRPM8, TRPM7, TRPM5 PRCP 3810/4885HCRTR1 264/4885HCRTR2 391/4885
US-20240358611-A1 COMPOSITIONS AZI2, NISCH, CIP2A PRCP 4858/4885HCRTR1 3846/4885HCRTR2 4172/4885
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS TRPM8, TRPM7, TRPM5 PRCP 2922/4885HCRTR1 3527/4885HCRTR2 3466/4885
US-12528801-B2 Substituted azacyles as TRPM8 modulators TRPM8, TRPM7, TRPM4 PRCP 4236/4885HCRTR1 245/4885HCRTR2 404/4885
US-20250387310-A1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT TAS2R30, TAS2R1, TAS2R20 PRCP 4246/4885HCRTR1 4175/4885HCRTR2 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.